CAMBRIDGE, Mass.--(BUSINESS WIRE)--Javelin Pharmaceuticals, Inc. (Amex: JAV), a leading developer of novel products for pain management, today announced that Dr. Eric Lang has been appointed Vice President of Clinical Research. Dr. Lang comes from Novartis, where he was most recently the Global Head of Clinical Research and Development for Analgesia for its Consumer Health Division. In that capacity, he was responsible for the design and implementation of the clinical strategy for its global analgesics franchise. Dr. Lang was a member of the team which obtained US FDA regulatory approval for Novartis’ Voltaren Sodium Gel® (topical diclofenac sodium) in 2007, the first topical NSAID approved in the USA for osteoarthritis. Prior to Novartis, Dr. Lang held roles of increasing responsibility at Johnson & Johnson for seven years. Dr. Lang received his medical degree at Ben Gurion University of the Negev in Beer Sheba, Israel and completed an acute and chronic pain fellowship at Emory University Medical School.
